<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328532</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02794-53</org_study_id>
    <nct_id>NCT04328532</nct_id>
  </id_info>
  <brief_title>MRI Screening of Placenta Adhesion Abnormalities</brief_title>
  <acronym>DIANE</acronym>
  <official_title>MRI Screening of Placenta Adhesion Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placenta Adhesion Abnormalities (PAA) are the consequence of an excessive invasion of the&#xD;
      placenta within the myometrium. PAA are related to severe maternal pregnancy outcomes,&#xD;
      especially in case of incidental discovery during delivery that increase the risk of&#xD;
      intraoperative massive bleeding, hysterectomy and even maternal death. Ultrasound is the&#xD;
      standard modality for diagnosing PAA, but Magnetic Resonance Imaging (MRI) has been&#xD;
      increasingly performed in the case of inconclusive sonographic findings. However, standard&#xD;
      morphological MRI sequences appear as insufficient to improve the sensitivity and specificity&#xD;
      values for detecting PAA, while quantitative MRI may be more efficient.&#xD;
&#xD;
      The main objective of this study is to characterize the diagnostic performance of&#xD;
      quantitative MRI parameters (mainly Apparent Diffusion Coefficient, T2 and T2*) reflecting&#xD;
      placental perfusion and/or oxygenation at high field, without injection of gadolinium-based&#xD;
      agent, for the detection of PAA in women with ongoing pregnancy between 30 and 38 weeks of&#xD;
      gestation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2020</start_date>
  <completion_date type="Anticipated">October 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective interventional clinical cohort study, monocentric, controlled, non-randomized, open.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the ROC curve of the T2 relaxation time mean value</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the ROC curve of the T2* relaxation time mean value</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the ROC curve of the Apparent Diffusion Coefficient mean value</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Placenta; Implantation</condition>
  <arm_group>
    <arm_group_label>Pregnancy with suspicion of PAA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnancy without suspicion of PAA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI examination (45 min max) with oxygen delivery for 10 min</description>
    <arm_group_label>Pregnancy with suspicion of PAA</arm_group_label>
    <arm_group_label>Pregnancy without suspicion of PAA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant participant between 30 and 38 weeks of gestation,&#xD;
&#xD;
          -  Age ≥18 years old,&#xD;
&#xD;
          -  Participant who completed the preliminary medical examination,&#xD;
&#xD;
          -  Participant who has received full information about the organization of the research&#xD;
             and has signed her informed consent.&#xD;
&#xD;
          -  Participant planning to give birth at CHRU of Nancy&#xD;
&#xD;
        Additional criteria for participants in the &quot;Pregnancy without suspicion of PAA&quot; group:&#xD;
&#xD;
          -  Multiparous participant (having had at least one childbirth),&#xD;
&#xD;
          -  Participant presenting one of the risk factors for PAA (low-lying or covering placenta&#xD;
             discovered during routine ultrasound) but without uterine scar.&#xD;
&#xD;
        Additional criteria for participants in the &quot;Pregnancy with suspicion of PAA&quot; group:&#xD;
&#xD;
          -  Participant with a low-lying or covering placenta discovered during routine&#xD;
             ultrasound,&#xD;
&#xD;
          -  Participant with a uterine scar.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancy,&#xD;
&#xD;
          -  Participant presenting at least one contraindication or restriction to performing an&#xD;
             MRI as described in the protocol, in accordance with the current recommendations,&#xD;
&#xD;
          -  Participant unable to understand or follow study procedure,&#xD;
&#xD;
          -  Person referred to in Articles L. 1121-6 to L. 1121-8, L1122-2 and L. 1122-1-2 of the&#xD;
             Public Health Code.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charline BERTHOLDT, MI</last_name>
    <phone>+33 3 83 34 43 12</phone>
    <email>c.bertholdt@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charline BERTHOLDT, MI</last_name>
      <phone>+33 3 83 34 43 12</phone>
      <email>c.bertholdt@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>BERTHOLDT Charline</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

